Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bromodomain and extraterminal domain (BET) proteins are a family of proteins, including BRD2, BRD3, BRD4, and BRDT, characterized by two tandem N-terminal bromodomains that recognize acetylated lysine residues on histones, an extraterminal (ET) domain involved in recruiting components of the transcriptional complex, and in some members (BRD4/BRDT), a C-terminal domain important for protein interactions. BET proteins regulate chromatin structure and gene expression, playing crucial roles in cellular processes such as cell cycle progression, proliferation, differentiation, inflammation response, and oncogenesis. Inhibitors of BET proteins block the interaction between bromodomains and acetylated histones, repressing transcriptional programs driven by key oncogenes.
Reversibly binds to bromodomains, preventing interaction with acetylated histones and disrupting chromatin targeting, repressing transcriptional programs.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bromodomain and Extraterminal Domain Proteins (BET Proteins).